Healer’s first webinar of the year provided a research update on studies examining cannabis used as a treatment for different neurologic conditions.
On January 10, 2024, at 7:00pm ET, Dustin Sulak, DO, board member of the Society of Cannabis Clinicians and co-founder of Healer, hosted a webinar discussing several studies using cannabis as a medicine. The purpose of the webinars, he explained, is to keep people up to date on the studies being published on medical cannabis by providing highlights and commentary, especially on the cannabinoids used. The free, two-hour webinar presented six case studies within the past six months that tested cannabis as a treatment for multiple sclerosis (MS), neuropathic pain, and Tourette syndrome. Guest speaker Daniel Stein, MD, who has more than 25 years of experience practicing neurology, also provided commentary and insights from his own practice.
The first two studies discussed multiple sclerosis. One study, an ad hoc evaluation, examined studies of MS patient muscle spasticity with a cannabis-derived medication in an oral spray, and the second one reviewed medical records of MS patients using cannabis and noted changes in pain, spasticity, and other symptoms. Both Dr. Sulak and Dr. Stein discussed the results of the studies, particularly the design, limitations, and the treatment itself.
The next two studies examined neuropathic pain in MS patients. The first study was a randomized, double-blind, placebo-controlled trial with three different types of cannabis-based treatments, and the second study involved patients using vaporizers for their medical cannabis. For these studies, the placebo groups, side effects, and the endocannabinoid system were the focus of discussion.
Finally, the last two studies covered Tourette syndrome, which currently has limited treatment options, Dr. Sulak noted. In the first study, a double-blind, randomized, placebo-controlled trial, the patients received cannabis-derived medication in a spray to treat their tics. The second, smaller study involved an oral dose of cannabinoids to treat tics. Dr. Sulak also shared results from treating one of his own patients with Tourette’s and discussed the possibility of cannabis improving quality of life for patients.
After the discussion of the studies, the presentation was open for attendees to ask any questions. Topics included the possibility of cannabinoids slowing down the progression of MS, the effects of different medication delivery methods, cannabinoids as sleep aids, and more.
Find more information on upcoming Healer.com webinars here.